Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Prepared: November 29, 2018
1 of 42
CURRICULUM VITAE
Name: Shaun R Coughlin, MD, PhD Position: Global Head, Cardiovascular and Metabolic Diseases
Novartis Institutes of Biomedical Research Professor Emeritus, Step A/S
Cardiovascular Research Institute, Department of Medicine, Department of Cellular and Molecular Pharmacology
University of California, San Francisco Address: Novartis Institutes of Biomedical Research
22 Windsor Street 4D-320A Cambridge, MA 02141
Email: [email protected]
EDUCATION 1972 - 1976 Massachusetts Institute of
Technology S.B. Biology
1972 - 1976 Massachusetts Institute of Technology
S.B. Physics
1975 - 1976 Massachusetts Institute of Technology
S.M. Biochemistry and Metabolism
1976 - 1981 Massachusetts Institute of Technology
Ph.D. Neural and Endocrine Regulation
M. Moskowitz
1976 - 1982 Harvard Medical School (Harvard-M.I.T. Division of Health Sciences and Technology)
M.D.
1982 - 1984 Massachusetts General Hopsital Residency Internal Medicine
1984 - 1986 University of California, San Francisco
Cardiology Fellow and Postdoctoral Fellow
L.T. Williams
LICENSES, CERTIFICATION 1986 Diplomat, Internal Medicine
1982 Massachusetts
1984 California
Prepared: November 29, 2018
2 of 42
PRINCIPAL POSITIONS HELD 1985 - 1986 Howard Hughes Medical Institute Associate
1986 - 1991 University of California, San Francisco Assistant Professor In Residence
Medicine (Cardiology)
1986 - 1990 Howard Hughes Medical Institute Assistant Investigator
1986 - 1991 University of California, San Francisco Associate Staff Cardiovascular Research Institute
1991 - present University of California, San Francisco Senior Staff Cardiovascular Research Institute
1991 - 1992 University of California, San Francisco Associate Professor In Residence
Medicine (Cardiology)
1992 - 1996 University of California, San Francisco Associate Professor Ladder Rank
Medicine (Cardiology)
1992 - 1996 University of California, San Francisco Associate Director Cardiovascular Research Institute
1996 - 2017 University of California, San Francisco Professor Ladder Rank
Medicine (Cardiology)
1997 - 2017 University of California, San Francisco Professor (joint appointment)
Molecular and Cellular Pharmacology
1997 - 2017 University of California, San Francisco Director Cardiovascular Research Institute
2006 - 2017 University of California, San Francisco Distinguished Professor of Cardiovascular Biology and Medicine
Cardiovascular Research Institute
2017 - present Novartis Global Head Cardiovascular and Metabolism
Prepared: November 29, 2018
3 of 42
OTHER POSITIONS HELD CONCURRENTLY 1991 - 2017 University of California, San Francisco Member Molecular
Medicine Program (postgrad training program)
1992 - 2017 University of California, San Francisco Member Biomedical Sciences Program (predoctoral training)
1992 - 2017 University of California, San Francisco Member Program in Biological Sciences (predoctoral training)
1995 - 2001 University of California, San Francisco Director Daiichi Research Center
HONORS AND AWARDS 1972 National Merit Scholar
1975 Phi Beta Kappa, M.I.T.
1976 Sigma Xi, M.I.T.
1976 Harvard National Scholar, Harvard Medical School
1978 Medical Scientist Training Program Fellow, Harvard Medical School
1979 Insurance Medical Scientist Scholar, Insurance Medical Scientist Scholarship Fund, Springfield, MA
1982 Leon Resnick Award for Excellence and Accomplishment in Research, Harvard Medical School
1982 American Heart Association Stroke Research Fellowship
1982 M.D. Magna Cum Laude, Harvard Medical School
Prepared: November 29, 2018
4 of 42
1990 John J. Sampson Research Award, AHA California Affiliate (highest score for Grant-in-Aid)
1991 Established Investigator Award, American Heart Association
1991 ASCI Plenary Session Presentation
1991 AFCR Henry Christian Award
1991 Young Investigator Award, WSCI
1992 American Society for Clinical Investigation.
1994 Syntex Prize in Receptor Pharmacology.
1995 Western Association of Physicians
1997 American Association of Physicians
1998 Outstanding Investigator Award, American Federation of Medical Research
2000 Hoeg Award, American Heart Association
2001 Beyer Visiting Professor, University of Wisconsin MSTP Program
2002 Belfer Visiting Professor, Johns Hopkins School of Medicine
2002 Elected to American Academy of Arts and Sciences
2003 Pasarow Foundation Award for Cardiovascular Research
2003 Basic Science Prize, American Heart Association
2004 Borun Visiting Professor, UCLA
2004 14th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cardiovascular Research
2004 Elected to National Academy of Sciences
2004 Elected to Institute of Medicine of the National Academies (now National Academy of Medicine)
2005 48th Annual Faculty Research Lecture, UCSF
Prepared: November 29, 2018
5 of 42
2006 Bristol-Myers Squibb Freedom to Discover Unrestricted Grant
2006 Stanley Korsmeyer ASCI Award
2007 Distinguished Scientist of the American Heart Association
2008 Earl Benditt Award, ASIP/NAVBO
2009 Wu Visiting Professor, Columbia
2010 Keystone GPCR Meeting, Keynote Lecture
2011 Metcalfe Lecture, OHSU
2011 Bristow Lecture, University of Illinois, Chicago
2011 Distinguished Career Award, International Society on Thrombosis and Haemostasis
2011 Louis and Arthur Lucian Award, McGill University
2012 Distinguished Scientist Lecture, American Heart Association
2014 Research Achievement Award, American Heart Association
2015 UCSF 150th Anniversary Alumni Excellence Award
KEYWORDS/AREAS OF INTEREST molecular biology, cell biology, cardiovascular biology, hemostasis and thrombosis, proteases, protease-activated receptors, G protein-coupled receptors, signaling mechanisms, therapeutic development
PROFESSIONAL ACTIVITIES MEMBERSHIPS 1975 - Phi Beta Kappa
1976 - Sigma Xi
1986 - American Federation for Clinical Research
1989 - American Heart Association Council on Basic Science
1992 - American Society for Clinical Investigation
1992 - American Society for Investigative Pathology
1994 - North American Vascular Biology Organization
Prepared: November 29, 2018
6 of 42
1995 - Western Association of Physicians
1997 - American Association of Physicians
1998 - Association of University Cardiologists
2002 - American Academy of Arts and Sciences
2004 - National Academy of Sciences
2004 - Institute of Medicine of the National Academies
SERVICE TO PROFESSIONAL PUBLICATIONS 1992 - 2000 Editorial Board, Trends in Cardiovascular Medicine
1994 - 2000 Editorial Board, Molecular Medicine
1998 - 2008 Editorial Board, Journal of Clinical Investigation
2012 - present Editorial Board, Journal of Clinical Investigation
- Ad hoc for multiple journals (Science, Nature, Cell, Dev. Cell, Nature Medicine, PNAS, etc.)
INVITED PRESENTATIONS - INTERNATIONAL 1992 Third Biennial Meeting on Blood Coagulation and Platelet
Biology
1992 Senri International Symposium on Atherosclerosis
1992 International Society for Applied Cardiovascular Biology
1992 International Symposium on the Biology of Vascular Cells
1992 Ares-Serono Symposium on G protein-coupled receptors, Geneva
1993 XIVth International Congress on Thrombosis and Haemostasis
1993 European Biochemical Society Meeting, Vienna
1995 International Symposium on Endothelium
1995 Alfred Benzon Symposium on G Protein-Coupled Receptors, Copenhagen
1995 Keynote speaker, IXth annual Vessel Research Conference, Tokyo
1996 Keynote Speaker, Japanese Society for Haemostasis and Thrombosis, Yamanashi, Japan
1996 International Society of Haematology, Singapore
1996 International Conference on Cell Biology, Symposium talk
Prepared: November 29, 2018
7 of 42
1997 Keynote Speaker, 117th Japanese Pharmacology Association Meeting
1997 International Congress of Biochemistry and Molecular Biology, Symposium talk
1997 Owren Memorial Lecture, Oslo, Norway
1999 International Society for Thrombosis and Hemostasis Protease Symposium
2001 State of the Art Lecture, International Society for Thrombosis and Haemostasis Congress, Paris
2002 NL Congressi Annual Meeting on Thrombosis, La Thuile
2002 Molecular Medicine 2002, Reykjavik
2003 Symposium Lecture, International Society for Thrombosis and Haemostasis Congress, Birmingham, UK
2004 Sixth International Winter Meeting on Coagulation - La Thuile
2005 Symposium Lecture, International Society for Thrombosis and Haemostasis Congress, Sydney, Australia
2006 Seventh International Winter Meeting on Coagulation - La Thuile
2007 International Society of Thrombosis and Haemostasis, Symposium talk, Geneva
2009 European Vascular Biology Organization Annual Meeting, Marseilles
2010 Mikamo Lecture, Japanese Cardiology Society annual meeting, Kyoto
2010 Keystone Meeting on Bioactive Lipids, Kyoto
2012 International Vascular Biology Meeting, Weisbaden
2012 Lucian Award Lecture, McGill
2013 International Society for Heart Research Congress
2014 Atherosclerosis, Thrombosis, and Vascular Biology Meeting, Toronto
2014 Merck Global Therapeutic Experts Forum Thrombosis
INVITED PRESENTATIONS - NATIONAL 1991 Ted Zimmerman Memorial Lecture, American Society for
Hematology
Prepared: November 29, 2018
8 of 42
1992 Gordon Conference on Hemostasis and Thrombosis.
1992 Gordon Conference on Vascular Biology
1992 FASEB Conference on Thrombin.
1992 Cold Spring Harbor Symposium on The Cell Surface.
1992 Thrombosis Sessions, AHA National Meeting.
1993 Gordon Conference on Molecular Pharmacology
1993 Keystone Symposium on Cardiovascular Development
1993 Bugher Lecture, Harvard Medical School
1993 AFCR/ASCI/AAP National Meeting, Program of Excellence Symposium
1993 Restenosis Summit
1993 FASEB Protease Symposium
1993 Gordon Conference on Atherosclerosis
1993 XIVth International Congress on Thrombosis and Haemostasis
1993 American Heart Association Molecular and Cellular Biology of the Vascular Wall.
1993 AHA National Meeting
1994 Gordon Conference on Vascular Biology
1994 Keystone Symposium on Endothelial Biology
1994 Keystone Symposium on Proteases
1994 Pine Ridge Conference on Genetics and Thrombosis
1994 Massachusetts General Hospital Cardiology Grand Rounds
1994 Beth Israel Seminars in Medicine Series
1994 FASEB Meeting
1994 Leaders in Life Sciences: A Lecture Series for Venture Capitalists
1994 AHA National Meeting
1995 Gordon Conference on Molecular Pharmacology
1995 Distinguished Seminar Series, National Jewish Center, Denver
1995 Year in Medicine - Cardiology at AFCR/ASCI/AAP annual meeting
Prepared: November 29, 2018
9 of 42
1995 American Thoracic Society: Symposium on Molecular and Cellular Biology of G Protein-Coupled Receptors.
1995 Gordon Conference on Atherosclerosis
1995 Gordon Conference on Second Messengers and Protein Phosphorylation
1995 American Society of Hematology (ASH) national meeting
1995 Massachusetts General Hospital Cardiology Grand Rounds
1996 University of Washington, Seattle, Biochemistry Lecture Series
1996 Keystone Conference, Molecular Biology of the Cardiovascular System
1996 AHA Conference on Vascular Biology
1996 Gordon Conference on Hemostasis and Thrombosis
1996 Gordon Conference on Vascular Biology
1996 AHA National Meeting, Symposium talk
1997 Gordon Conference on Molecular Pharmacology
1997 Molecular Medicine Series Lecture, Duke.
1997 Vascular Biology '97, Symposium talk
1997 Thrombosis Sol Sherry Distinguished Lecture, AHA National Meeting
1997 Woznicki Lecture, Baylor
1998 Keystone Symposium on Specificity in Signal Transduction
1998 Invited speaker, Scripps Vascular Biology Retreat
1998 Vascular Biology ‘98
1998 FASEB ‘98 Symposium on Protease-Activated Receptors
1998 FASEB ‘98 Cardiac Pathology Session, Keynote talk
1998 FASEB ‘98 Symposium on Current Mechanisms of Blood Coagulation
1998 Gordon Conference on Hemostasis
1998 Gordon Conference on Vascular Biology
1998 Gordon Conference on Proteolytic Enzymes and Their Inhibitors
1999 Gordon Conference on Molecular Pharmacology
Prepared: November 29, 2018
10 of 42
1999 National Academy of Sciences Colloquium on Proteolytic Enzymes and Physiological Regulation
1999 Nossel Memorial Lecture, Columbia University Medical School
1999 Gladstone Institutes Annual Retreat, Guest speaker
1999 Medical Grand Rounds, Stanford
1999 Roon Award Lecture, Scripps
1999 Cardiology Grand Rounds, Washington University, St. Louis
1999 Honors Lecture, NYU
2000 Dueul Conference
2000 Hoeg Award Lecture, American Heart Association
2000 FASEB 2000 Signaling Meeting, Copper Mountain
2000 Gordon Conference on Vascular Biology
2000 Keynote Speaker, U. Michigan Ann Arbor Cardiovascular Symposium
2000 UT Southwestern Molecular and Developmental Biology Series
2001 UC Davis Molecular Biology Lecture Series
2001 AAAS Annual Meeting Signaling Symposium
2001 Keynote speaker, University of Wisconsin M.D., Ph.D. program symposium
2001 Keynote, ASBMB FASEB Meeting on Proteolysis and Regulation
2001 FASEB ASIP Symposium, Proteases and Vascular Biology
2001 FASEB ASPET Symposium, G protein-coupled receptors in Endothelial Cell Signaling
2001 American Chemical Society Symposium on PARs
2001 Chiron lecture series
2001 Genentech lecture series
2001 Cold Spring Harbor Meeting on Proteolysis and Biological Control
2001 U Pennsylvania, Thrombosis and Cardiovascular Biology Series
2001 UC Davis, Biochemistry Series
Prepared: November 29, 2018
11 of 42
2001 Temple University, 20th Jeanette Piperno Memorial Lecture
2001 American Heart Association Annual Meeting, Symposium on Tissue Factor Biology
2002 Proteolysis Gordon Conference
2002 Belfer Lecture, Johns Hopkins School of Medicine
2002 Hemostasis Gordon Conference
2002 67th Cold Spring Harbor Symposium on Quantitative Biology
2002 Keynote speaker, Oregon Health Sciences University MSTP Retreat
2002 Russell Ross Memorial Lecture in Vascular Biology, AHA National Meeting
2002 American Society of Hematology National Meeting, Vascular Biology Symposium
2003 Vascular Biology Gordon Conference
2003 Stanford Hematology seminar
2003 Massachusetts General Hospital, Cardiology Grand Rounds
2003 Stuart Stone Memorial Lecture, FASEB Summer Conference on Vascular Biology
2003 American Heart Association Young Investigators Forum Keynote, San Francisco
2003 Evans Lecture, Stanford
2003 Russel Ross Memorial Lecture in Vascular Biology, AHA
2004 University of Washington, Seattle Symposium on Haemostasis
2004 Borun Visiting Professor, UCLA
2004 Bristol-Meyers Squibb Cardiovascular and Metabolic Diseases Colloquium
2004 American Society of Hematology National Meeting, Thrombosis and Vascular Biology Symposium
2005 Platelet Gordon Conference
2005 Vascular Biology Gordon Conference
2005 Atherosclerosis Gordon Conference
2005 FASEB Symposium
Prepared: November 29, 2018
12 of 42
2005 UT Southwestern Biochemistry Series
2005 FASEB Summer Protease meeting
2005 Harvard-MIT Program in Health Sciences and Technology 35th Anniversary
2006 Stanford Cardiovascular Research Series
2006 Keystone meeting on Atherothrombosis Co-organizer
2006 Cleveland Clinic Annual Page Lecture
2006 University of Illinois, Urbana. Molecular Biology Training Program Lecture
2006 Stanley Korsmeyer Award Lecture, ASCI
2006 UNC Chapel Hill, Genetics and Molecular Biology Seminar Series
2006 University of Arkansas Medical Center Physiology Series
2006 Bristol-Meyers Squibb Annual Cardiovascular and Metabolism Awards Research Colloquium
2007 Molecular Pharmacology Gordon Conference Keynote Lecture
2007 Platelet and Megakaryocyte Gordon Conference
2007 UC San Diego Visiting Physician-Scientist Scholar
2007 Mayo Clinic Biochemistry and Molecular Biology Series
2007 American Thoracic Society Annual Meeting
2007 FASEB Hemostasis and Thrombosis Meeting
2007 Massachusetts General Hospital Paul Dudley White Lecture
2007 University of Michigan, Ann Arbor, Frank N. Wilson Visiting Professor
2007 MeHarry Medical School
2008 Keynote, Gordon Research Conference on Plasminogen Activation and Extracellular Proteolysis
2008 Benditt Award Lecture, NAVBO/FASEB annual meeting
2008 University of Pennsylvania Cardiovascular Institute (CVI) inaugural symposium
2008 Keynote, Rockefeller GPCR meeting
2009 University of Delaware
2009 Keystone Conference, Lipid Signaling
Prepared: November 29, 2018
13 of 42
2009 University of Texas Southwestern, University Lecture series
2009 Keynote, AHA-ATVB annual meeting, Washington, D.C.
2009 FASEB Lysophospholipid Mediators
2009 AHA Annual Meeting, Orlando
2009 Columbia University Medical School, Wu Visiting Professor
2010 Keynote Lecture, Keystone GPCR meeting, Breckenridge, CO
2010 Keynote, Hemostasis Gordon Conference, New Hampshire
2010 UC Berkeley Molecular and Cellular Biology Department Seminar
2010 UC Berkeley Nutritional Biochemistry and Toxicology Department Seminar
2011 Molecular Pharmacology Gordon Conference
2011 Metcalfe Lecture, Oregon Health Sciences University
2011 Yale Cardiovascular Research Center Inaugural Symposium
2011 Bristow Lecture, University of Illinois Chicago
2011 FASEB Protease meeting
2012 Extracellular Proteolysis Gordon Conference
2012 Keynote, University of Kentucky Cardiovascular Research Symposium
2012 Distinguished Scientist Lecture, American Heart Association National Meeting
2012 Keynote, 41st Workshop on Hemostasis, Thrombosis and Atherosclerosis, CHoP/UPenn
2013 Deuel Conference Journal of Lipid Research Lecture
2013 Keynote AHA Basic Cardiovascular Sciences Annual Meeting
2013 Keynote Stanford Cardiovascular Institute Annual Retreat
2013 ASBMB Syposium on Proteases
2013 Cotran Lecture, Children's Hospital, Boston
2013 Cardiovascular Grand Rounds, Brigham and Women's Hospital
Prepared: November 29, 2018
14 of 42
2013 Keynote, Annual Earl Davie Symposium, University of Washington
2014 Gordon Research Conference on Extracellular Proteolysis
2014 Arnsdorf Lecture, University of Chicago
2014 Keynote, NAVBO Annual Meeting, Asilomar
2015 Keynote session, Gordon Research Conference on Molecular Pharmacology
2015 Annual student-invited seminar speaker, Pharmacology Graduate Program, UCSD
2016 Duke Cardiovascular Research Series
2016 NYU Karpatkin Lecture
2016 American Society for Hematology Annual Meeting, San Diego
2017 Vascular Cell Biology Gordon Conference
2017 Stanford Drug Discovery Symposium
2017 ASBMB Protease Meeting
2017 American Heart Association Scientific Sessions
INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS 1999 Symposium on Degenerative Diseases, UCSF
1999 Young Presidents Organization, UCSF
2000 PIBS retreat, UCSF
2000 Cardiology Grand Rounds, UCSF
2000 BMS/CVRI retreat, UCSF
2001 Cardiology Grand Rounds/UCSF
2001 Pathology and Laboratory Medicine Grand Rounds/UCSF
2001 UCSF Friday Faculty Research Talk
2002 Bridge Conference, Medicine, UCSF
2002 Angiogenesis Symposium, UCSF
2002 Medical Grand Rounds, San Francisco VA Medical Center
2002 Dean's Series for Medical Students, UCSF
2003 UCSF Friday Faculty Research Talk
2003 UCSF Dermatology seminar
2003 UCSF Cardiology Grand Rounds
Prepared: November 29, 2018
15 of 42
2004 UCSF Cellular and Molecular Pharmacology Faculty talk
2004 UCSF PIBS retreat
2004 UCSF PSPG retreat
2005 UCSF Biomedical Sciences Program Retreat
2005 UCSF Faculty Research in Progress Parnassus
2006 UCSF Cardiology Grand Rounds
2006 UCSF Medical Grand Rounds
2007 UCSF Cardiology Grand Rounds
2008 UCSF Friday Faculty Research Talk
2008 UCSF Research talk to PIBS students
2008 UCSF Cardiology Grand Rounds
2008 UCSF Tetrad Retreat
2009 UCSF Tobacco Research and Education Symposium, wrap-up speaker.
2010 UCSF Friday Faculty Research talk
2012 UCSF Cardiology Grand Rounds
2013 UCSF Friday Faculty Research Talk
2013 UCSF Biomedical Sciences Program Symposium
GOVERNMENT AND OTHER PROFESSIONAL SERVICE 1995 - NIH-HLBI Peer review committee for Thrombosis SCORs
1996 - NIH-NHLBI Concept review special emphasis panel on emerging areas in thrombosis and hemostasis research.
2003 - 2007 Hemostasis Thrombosis (HT) Study Section, NIH HLBI
2005 - NIH NHLBI Working Group on predicting cardiovascular risk
2006 - NIH NHLBI Working Group on diagnosis and treatment of thrombosis and bleeding
2006 - NIH NHLBI Working Group on inflammation and thrombosis
2006 - NIH NINDS Working Group on stroke
2007 - 2010 NIH National Heart, Lung, Blood Advisory Council
2008 - Review Committee, NHLBI Comprehensive Sickle Cell Centers Program
2009 - NHLBI Translational Research Oversight Committee
Prepared: November 29, 2018
16 of 42
2012 - 2013 NIH SMARTT Program Scientific Review Board
UNIVERSITY AND PUBLIC SERVICE SERVICE ACTIVITIES SUMMARY My main service activities are related to my role as CVRI Director to foster cardiovascular research at UCSF. Activities have included planning the program and design of the Smith Cardiovascular Research Building, securing funding for this $254M project, shepherding its construction, recruiting 18 new faculty members in the past five years, raising funds for the latter, and supporting the development of these faculty members.
UCSF CAMPUSWIDE 1993 - 1994 Curriculum Committee, Biomedical Sciences Program
1993 - Chair of Search Committee, Vascular Biology Recruitment, Gladstone/UCSF
1993 - 2001 Daiichi Research Center Advisory Board
1994 - 1995 Research Committee - Chancellor's Strategic Planning Board
1997 - Chair, Search Committee, Director, Gladstone Institute for Cardiovascular Disease
1997 - Chancellor’s Committee on Industry Relations and Conflicts of Interest
1997 - Mission Bay Task Force
1998 - 1999 Parnassus Planning Committee
1998 - 1999 GCRC Steering Committee
1999 - Advisory Committee, Gladstone Institutes for Cardiovascular Diseases
1999 - HHMI Faculty Candidate Selection Committee
1999 - Search Committee, Assistant Vice Chancellor Industry Relations
1999 - 2000 Mission Bay University-Industry Partnership Committee
2000 - Parnassus Heights Research Space Committee
2000 - Strategic Planning Committee for Clinical Space
2000 - Co-developed proposal for Center for Genetics of Complex Diseases and Therapeutics, UCSF – led to Institute for Human Genetics
2000 - Co-developed proposal for Center for Stem Cell Biology and Tissue Development, UCSF – led to Center for Regenerative Medicine
2002 - Chancellor's Release Space Committee
Prepared: November 29, 2018
17 of 42
2002 - 2005 Parnassus Leadership Council
2002 - 2013 UCSF MSTP Council
2002 - 2004 Executive Committee, Program in Human Genetics, UCSF
2002 - 2004 Search Committee for Director, UCSF Institute for Human Genetics
2002 - Committee to implement Stem Cell Biology and Tissue Development Program, UCSF
2002 - 2004 Search Committee for Director, Developmental and Stem Cell Biology
2002 - 2003 Search Committee for Dean, UCSF School of Medicine
2003 - 2005 Search Committee for Director, Gladstone Institutes of Cardiovascular Disease
2004 - 2005 UCSF Parnassus Leadership Committee
2004 - 2010 UCSF Heart and Vascular Center Executive Committee
2004 - 2010 Co-Chair, Planning Committee, UCSF Cardiovascular Research Building
2005 - 2010 Drove planning and secured funding ($254M) for the new Smith Cardiovascular Research Building, which opened on Mission Bay Campus in 2010
2005 - 2010 Building Committee, UCSF Cardiovascular Research Building
2005 - 2010 UCSF Genentech Hall Governance Committee
2005 - 2010 UCSF Mission Bay Leadership Committee
2006 - SFGH Academic Planning Committee
2006 - CTSA application committee
2007 - UCSF Clinical/Translational cores ad hoc committee
2008 - 2009 Helped explore and implement a new-to-UCSF model for arbitrage of gifts to finance Smith Building, its operations and programs.
2011 - 2012 UCSF, Long Range Development Planning Committee
2014 - 2015 Stewardship Review Committee for Chair, Microbiology and Immunology
2014 - 2015 Co-Chair, Search Committee for Dean of School of Medicine
2015 - 2016 Search Committee for VC Business Development, UCSF
2015 - 2016 ECVP committee to improve UCSF Industry, Technology & Alliances services
Prepared: November 29, 2018
18 of 42
2016 - 2017 Search Committee for Chair, Pediatrics, UCSF
SCHOOL OF MEDICINE 1991 - 2003 Cardiology fellow selection, UCSF- Research Track
1992 - 2007 Board of Directors, Cardiovascular Research and Education Foundation, CVRI/UCSF
1994 - 1997 Executive Committee, CVRI, UCSF
1995 - Department of Medicine Committee on Translational Research
1995 - Search Committee for Reproductive Endocrinology faculty
1995 - Search Committee for Cancer Research Institute faculty
1995 - Ad Hoc Committee of Organized Research Unit representatives for Biomedical Sciences Program
1995 - 2010 Executive Committee, UCSF's Molecular Medicine Program
1996 - 2004 Promotions Subcommittee, Department of Medicine
1997 - present Director, CVRI
1997 - 2007 Executive Committee, UCSF Biomedical Sciences Graduate Program
1997 - Search Committee, Chief, Cardiology Division, UCSF
1997 - present Chair or co-chair of Search Committees for new CVRI Faculty
1998 - 2004 Dean?s Fund Raising Advisory Committee (FRAC)
1999 - Dean?s Advisory Committee on Impacts of Clinical Initiatives
2000 - Chair, Search Committee, Director, Pacific Vascular Research Laboratory
2003 - Advisory Committee, UCSF Prostate Cancer SPORE
2007 - Search Committee, UCSF Chair of Medicine
2007 - 2008 Search Committee, UCSF Chief of Cardiology
2008 - 2009 Search Committee for Dean, UCSF School of Medicine
2009 - Search Committee, UCSF Chief of Pulmonary
2009 - Search Committee, UCSF Radiology, cardiovascular imaging researcher
2009 - 2017 School of Medicine Space Committee
2016 - 2017 Search Committee, UCSF Chair of Pediatrics
Prepared: November 29, 2018
19 of 42
- Ongoing: Multiple PPG and T32 advisory committees, Cardiology fellowship interviewer.
DEPARTMENTAL SERVICE 1997 - present UCSF Cardiovascular Research Institute Director
1997 - present UCSF Cardiovascular Research Institute Faculty search committees chair, co-chair or member
2008 - present UCSF Department of Medicine (Cardiology) and CVRI Presentations to Cardiology Fellowship Applicants on interview days; interview selected applicants
COMMUNITY AND PUBLIC SERVICE 1992 - 1996 Executive Committee, Thrombosis Council, American Heart
Association
1993 - 1996 Program Committee, Thrombosis Council, American Heart Association
1993 - Co-Chair, 1993 Gordon Conference on Atherosclerosis.
1995 - 1997 American Heart Association Katz Prize Committee
1996 - Research Committee, California Affiliate, American Heart Association
1997 - Program Committee, American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology
1997 - 2001 Chair, IUPHAR Nomenclature Subcommittee on PARs
1997 - Chair, 1997 Gordon Conference on Molecular Pharmacology
2000 - 2003 Myocyte Systems Committee, Alliance for Cell Signaling
2004 - 2008 Search and Screening Committee, National Academy of Sciences, Section 42
2006 - 2016 Scleroderma Research Foundation SAB
2012 - present Leducq Foundation Scientific Review Board, currently Chair
2012 - 2017 Council, American Association of Physicians
2006 - present Chair, Portola Pharmaceuticals SAB
2006 - 2012 Oklahoma Medical Research Foundation SAB
Prepared: November 29, 2018
20 of 42
TEACHING AND MENTORING TEACHING SUMMARY Despite substantial administrative duties, I am able to do some formal teaching. In recent years this has been in the GEMS and BMS225 courses for graduate students and hemostasis/thrombosis-related teaching to medical students as indicated.
FORMAL TEACHING Academic Yr Course No. & Title Teaching Contribution School Class
Size
2006 - present
Cardiology Grand Rounds at UCSF approximately every other year
speaker Medicine
2010 - present
BMS225A Human Disease: Technologies & Biomedical Applications
2-3 contact hours, 3-6 prep hours
Medicine ~30
2010 - present
GEMS Introduction to Human Biology and Medicine
3 contact hours, 3-6 prep hours
Medicine ~30
2010 - 2011 GEMS Demystifying Medicine, Physiology 181
3 contact hours, 3-6 prep hours
Medicine ~30
2014 - Organ Block 2 contact hours, 12 hours prep
Medicine ~150
2015 - 2016 Hemostasis Thrombosis Lecture
2 contact hours, 6 hours prep
Medicine ~150
MENTORING SUMMARY The majority of my teaching and mentoring activities center on training postdoctoral fellows and graduate students in my laboratory. There are 3 structure hours of group teaching weekly (1h journal club and 2h lab meeting), one formal one-on-one hour every two weeks, and more frequent ad hoc and working group meetings. Total contact hours per year are approximately 750. I have supervised approximately 40 postdoctoral fellows, with nearly all going on to research careers in academia or industry. Examples in academia include Mark Kahn (U Penn), JoAnn Trejo (UCSD), Robert Gerszten (MGH/Harvard) Stephen Hammes (U Rochester), Eric Camerer (PARRC-INSERM, Paris), and Ethan Weiss (UCSF). Examples in industry include David Hung (CEO-Medivation), Dan Lerner (CMO-TYRX), Harold Bernstein (Director, Clinical Research & Senor Principal Scientist, Merck), Rajita Pappu (Scientist, Genentech), and Jean Regard (Scientist, Novartis).
Prepared: November 29, 2018
21 of 42
Graduate students are listed above.
PREDOCTORAL STUDENTS SUPERVISED OR MENTORED Dates Name Program or
School Mentor Type Role Current
Position
1994 - 1998 Andrew Connolly
BMS Research/Scholarly Mentor
supervisor Prof. Pathology, Stanford
1998 - 2003 Courtney Griffin
BMS Research/Scholarly Mentor
supervisor Assoc. Member, OMRF, U Oklahoma Health Science Center
2000 - 2005 David Willison MSTP Research/Scholarly Mentor
supervisor Research Fellow, Child Psychiatry, UCLA
2008 - 2013 Arif Hussain MSTP Research/Scholarly Mentor
supervisor Medical Student
2009 - 2015 Adrian Barker BMS Research/Scholarly Mentor
supervisor BMS student
2012 - 2016 Eamon Balouch
UC Davis MSTP
Research/Scholarly Mentor
supervisor UC Davis MSTP student
POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED Dates Name Fellow Mentor Role Faculty Role Current
Position
- Research/Scholarly Mentor,Project Mentor,Career Mentor
~44 postdoctoral fellows trained-- see narrative
FACULTY MENTORING Dates Name Position while
Mentored Mentor Type Mentoring Role Current
Position
Prepared: November 29, 2018
22 of 42
Dates Name Position while Mentored
Mentor Type Mentoring Role Current Position
- Research/Scholarly Mentor,Project Mentor,Career Mentor
informal mentoring of CVRI junior faculty-- ongoing
VISITING FACULTY MENTORED 1992 - 1993 Prof Scot Soifer UCSF
1993 - 1994 Prof israel Charo UCSF/Gladstone
1998 - 1999 Prof Eric Rondeau U. Curie, Paris
2011 - 2012 Prof Erica DeCandia Catholic U. Hospital, Rome
RESEARCH AND CREATIVE ACTIVITIES RESEARCH AND CREATIVE ACTIVITIES SUMMARY Our laboratory seeks to define signaling mechanisms that govern cardiovascular biology and disease. Current areas of focus include: 1) Protease-Activated Receptors (PARs). a) Structure-Function. Our laboratory discovered and characterized PARs, a family of GPCRs that permit thrombin and related proteases to regulate the behavior of platelets and other cells. Mutational and biochemical studies suggest that PARs are activated by an elegant proteolytic mechanism. Thrombin cleaves the N-terminal exodomain of PAR1 to create a new N-terminus that then serves as a tethered peptide agonist, binding intramolecularly to the receptor's heptahelical bundle to effect transmembrane movement and G protein activation. While a substantial body of data from mutational and biochemical studies supports this model, an on-state crystal structure of PAR1 that confirms the tethered ligand mechanism and reveals how the tethered ligand docks and triggers transmembrane signaling is needed. In collaboration with Brian Kobilka's laboratory, we recently solved an off-state structure of PAR1 in complex with its antagonist vorapaxar. The structure explained the effectively irreversible action of vorapaxar and suggested a novel drug entry route and a possible contribution of entry kinetics to drug specificity –– areas of current inquiry. More importantly, the know-how acquired in solving this off-state structure has positioned us to take on the challenge of solving the PAR1 on-state structure. PAR1 couples to Gi, Gq and G12. We seek to solve structures of activated PAR1 in complex with these three G proteins. In addition to revealing the details of tethered ligand docking and transmembrane signaling, these structures will reveal how a single GPCR can couple to distinct G proteins; in addition to revealing basic mechanisms, the answer will likely provide structural insight into the mechanism of biased agonism. b) Physiology. Mammals have 4 PARs. Together with the coagulation cascade, these receptors link tissue injury to cellular responses that regulate blood clotting, inflammation, pain sensation, and perhaps cytoprotection and repair. PARs are necessary for platelet activation by thrombin, and the PAR1 antagonist vorapaxar was recently FDA-approved to prevent myocardial infarction and ischemic stroke in selected patients with known atherothrombotic disease (albeit at a cost of increased bleeding risk). Current work in this area focuses on better
Prepared: November 29, 2018
23 of 42
defining the roles of PAR function in platelets and endothelial cells in hemostasis and vascular integrity in mouse models of spontaneous bleeding. c) Embryonic Development. PARs also contribute to embryonic development. Par1 function in endothelial cells is appears to be necessary for normal vascular integrity in mouse embryos. Par2 appears to be necessary for normal placentation. Work to understand the mechanisms underlying these phenotypes is ongoing. d) Epithelial Biology. Recent work in the lab suggests that a local network comprised of membrane-tethered proteases matriptase and prostasin, their inhibitors, and Par2 may regulate epithelial structure and function. These molecules are co-expressed in many epithelial tissues from gut to glands to skin, and mouse and human genetic studies suggest possible roles in regulating epithelial integrity and other functions. We are using genetic and advanced microscopy to define the detailed roles of matriptase and Par2 in the periderm (apical) and basal layers of the skin of zebrafish embryos as a model epithelium. Our studies support an unexpected role in regulating epithelial cell extrusion, cell-cell junctions, proliferation and survival as well as epithelial-triggered inflammation. 2) Inflammation and Repair We have invested in developing a zebrafish model of response to vascular injury that allows visualization of hemostasis, neutrophil and macrophage recruitment and egress, resolution of thrombi, and endothelial repair with restoration of blood flow all within 24 h. The model is high-content and high-throughput. At the same time, we have developed methodology for F0 knockouts of genes in zebrafish that enables immediate analysis of loss of function of genes of interest. We are using this F0 knockout system to evaluate the importance of different cell types and pathways in this model, with focus on resolution of inflammation. We expect the general F0 knockout approach to be widely applicable as a complement to morpholinos and stable knockouts, and we are currently using it in other moderate throughput screening applications. 3) Evaluation of Intrinsic Pathway Function in Human Hemostasis and Thrombosis Human genetics and animal model studies support a role for coagulation factor XIa in thrombosis and raise the possibility that inhibition of FXIa might prevent thrombosis with less bleeding risk than current agents. Toward testing this hypothesis and in collaboration with Pfizer's Center for Therapeutic Innovation, we generated a fully human effector null IgG that is FXIa-specific and blocks thrombosis in two animal models without a detectable effect on hemostasis. A crystal structure of the FXIa-antibody complex confirmed occupancy of the FXIa active site. Efforts to out-license this molecule are in progress. Additionally, with the ultimate goal of developing preclinical models that predict bleeding risk in humans, we have developed a mouse model that features spontaneous GI bleeding that is highly platelet and coagulation-dependent. We are testing the effect of FXI and PAR3 deficiencies in this model to ascertain whether it might predict bleeding liabilities not detected in standard bleeding time another induced-bleeding models.
RESEARCH AWARDS - CURRENT 1. NIH HL07731 PI 50 % effort Coughlin (PI) NIH/NHLBI 09/01/2012 08/31/2017
Prepared: November 29, 2018
24 of 42
Molecular and Cellular Mechanisms of Cardiovascular Disease
$ 412450 direct/yr 1
T32 training grant. Renewal will be funded. 2. R01 HL121387 Corresponding PI (other PI
is B. Kobilka) Coughlin (PI)
NIH/NHLBI 01/15/2014 12/31/2017 Structural Basis of Protease-Activated Receptor
Function $ 562,704 direct/yr 1
Seeks to solve on-state structure of PAR1 to reveal mechanism of tethered ligand docking and basis for G protein specificity
3. R35 HL135755 PI 50 % effort Coughlin (PI) NIH/NHLBI 2/14/2017 12/312023 Structure-Function and Roles of Protease-Activated
Receptors $ ~500000 direct/yr 1
$ ~4200000 total
RESEARCH AWARDS - PAST 1. UCSF Pfizer CTI PI Coughlin (PI) Pfizer 08/11/2014 08/15/2016 A Clinical Probe to Define the Role of Novel
Antithrombotic Target in Humans $ 52276 direct/yr 1
Probes role of unprecedented target in human thrombosis 2. R01HL054737 PI Coughlin (PI) NIH/NHLBI 06/30/2013 04/30/2017 Molecular Genetics of Cardiac Cell Differentiation $ 238000 direct/yr
1
Zebrafish models of heart and vascular development 3. U54 HL119893 Co-PI of UCSF
Component with June Lee Palazzolo M (PI)
NIH/NHLBI 01/2014 01/2019 NHLBI Center for Accelerated Innovation. Provides incubator funding to projects with translational promise in CV arena. No funds to
Coughlin lab. Transferred PI to Dr. Lee 4.
Prepared: November 29, 2018
25 of 42
Additional grant funding history available upon request. Continuous NIH funding from 1980s-
2017.
PEER REVIEWED PUBLICATIONS 1. Coughlin SR, Moskowitz MA, Zetter BR, Antoniades HN, Levine L. Platelet-dependent
stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature. 1980 Dec 11; 288(5791):600-2. PMID: 7003399
2. Coughlin SR, Moskowitz MA, Antoniades HN, Levine L. Serotonin receptor-mediated stimulation of bovine smooth muscle cell prostacyclin synthesis and its modulation by platelet-derived growth factor. Proc Natl Acad Sci U S A. 1981 Nov; 78(11):7134-8. PMID: 7031670
3. Glassberg, M.K., Bern, M.M., Coughlin, S.R., Haudenschild, C.C., Hoyer, L.W., Antoniades, H.N., and Zetter, B.R. (1982) Cultured endothelial cells derived from human iliac arteries. In Vitro l8(l0):859-866.
4. Coughlin SR, Moskowitz MA, Levine L. Identification of a serotonin type 2 receptor linked to prostacyclin synthesis in vascular smooth muscle cells. Biochem Pharmacol. 1984 Feb 15; 33(4):692-5. PMID: 6322808
5. Garrett JS, Coughlin SR, Niman HL, Tremble PM, Giels GM, Williams LT. Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet-derived growth factor receptors. Proc Natl Acad Sci U S A. 1984 Dec; 81(23):7466-70. PMID: 6095298
6. Coughlin SR, Lee WM, Williams PW, Giels GM, Williams LT. c-myc gene expression is stimulated by agents that activate protein kinase C and does not account for the mitogenic effect of PDGF. Cell. 1985 Nov; 43(1):243-51. PMID: 3000601
7. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A. 1986 Feb; 83(3):674-8. PMID: 3456163
8. Simpson P, Bishopric N, Coughlin S, Karliner J, Ordahl C, Starksen N, Tsao T, White N, Williams L. Dual trophic effects of the alpha 1-adrenergic receptor in cultured neonatal rat heart muscle cells. J Mol Cell Cardiol. 1986 Nov; 18 Suppl 5:45-58. PMID: 3027351
9. Starksen NF, Simpson PC, Bishopric N, Coughlin SR, Lee WM, Escobedo JA, Williams LT. Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proc Natl Acad Sci U S A. 1986 Nov; 83(21):8348-50. PMID: 3022291
10. Letterio JJ, Coughlin SR, Williams LT. Pertussis toxin-sensitive pathway in the stimulation of c-myc expression and DNA synthesis by bombesin. Science. 1986 Nov 28; 234(4780):1117-9. PMID: 3465038
11. Kacich RL, Williams LT, Coughlin SR. Arachidonic acid and cyclic adenosine monophosphate stimulation of c-fos expression by a pathway independent of phorbol ester-sensitive protein kinase C. Mol Endocrinol. 1988 Jan; 2(1):73-7. PMID: 2840568
Prepared: November 29, 2018
26 of 42
12. Coughlin SR, Barr PJ, Cousens LS, Fretto LJ, Williams LT. Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J Biol Chem. 1988 Jan 15; 263(2):988-93. PMID: 2447083
13. Escobedo JA, Navankasatussas S, Cousens LS, Coughlin SR, Bell GI, Williams LT. A common PDGF receptor is activated by homodimeric A and B forms of PDGF. Science. 1988 Jun 10; 240(4858):1532-4. PMID: 2836953
14. Kavanaugh WM, Williams LT, Ives HE, Coughlin SR. Serotonin-induced deoxyribonucleic acid synthesis in vascular smooth muscle cells involves a novel, pertussis toxin-sensitive pathway. Mol Endocrinol. 1988 Jul; 2(7):599-605. PMID: 2842665
15. Coughlin SR, Keating MT. The platelet-derived growth factor system. Cancer Treat Res. 1989; 47:169-76. PMID: 2576996
16. Coughlin SR, Escobedo JA, Williams LT. Role of phosphatidylinositol kinase in PDGF receptor signal transduction. Science. 1989 Mar 3; 243(4895):1191-4. PMID: 2466336
17. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991 Mar 22; 64(6):1057-68. PMID: 1672265
18. Lanza F, Wolf D, Fox CF, Kieffer N, Seyer JM, Fried VA, Coughlin SR, Phillips DR, Jennings LK. cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins. J Biol Chem. 1991 Jun 5; 266(16):10638-45. PMID: 2037603
19. Liu LW, Vu TK, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem. 1991 Sep 15; 266(26):16977-80. PMID: 1654318
20. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991 Oct; 88(4):1121-7. PMID: 1843454
21. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991 Oct 17; 353(6345):674-7. PMID: 1717851
22. Hung DT, Vu TH, Nelken NA, Coughlin SR. Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol. 1992 Feb; 116(3):827-32. PMID: 1309820
23. Hung DT, Vu TK, Wheaton VI, Charo IF, Nelken NA, Esmon N, Esmon CT, Coughlin SR. (1992) "Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure.? J Clin Invest. 89:444-50. PMID: 1310695
24. Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest. 1992 Apr; 89(4):1350-3. PMID: 1313452
25. Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu TK, Wheaton VI, Turck CW, Coughlin SR. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem. 1992 Jul 5; 267(19):13146-9. PMID: 1320011
Prepared: November 29, 2018
27 of 42
26. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992 Oct; 90(4):1614-21. PMID: 1328304
27. Hung DT, Wong YH, Vu TK, Coughlin SR. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem. 1992 Oct 15; 267(29):20831-4. PMID: 1328213
28. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993 Jan; 91(1):94-8. PMID: 8380817
29. Ishii K, Hein L, Kobilka B, Coughlin SR. Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. J Biol Chem. 1993 May 5; 268(13):9780-6. PMID: 7683662
30. Soifer SJ, Peters KG, O'Keefe J, Coughlin SR. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol. 1994 Jan; 144(1):60-9. PMID: 8291612
31. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb. 1994; 1 Suppl 1:S10-3. PMID: 9222884
32. Ishii K, Chen J, Ishii M, Koch WJ, Freedman NJ, Lefkowitz RJ, Coughlin SR. Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. J Biol Chem. 1994 Jan 14; 269(2):1125-30. PMID: 8288570
33. Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JW. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry. 1994 Mar 22; 33(11):3266-79. PMID: 8136362
34. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A. 1994 Mar 29; 91(7):2752-6. PMID: 8146186
35. Gerszten RE, Chen J, Ishii M, Ishii K, Wang L, Nanevicz T, Turck CW, Vu TK, Coughlin SR. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994 Apr 14; 368(6472):648-51. PMID: 8145852
36. Chen J, Ishii M, Wang L, Ishii K, Coughlin SR. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J Biol Chem. 1994 Jun 10; 269(23):16041-5. PMID: 8206902
37. Hein L, Ishii K, Coughlin SR, Kobilka BK. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem. 1994 Nov 4; 269(44):27719-26. PMID: 7961693
38. Ishii K, Gerszten R, Zheng YW, Welsh JB, Turck CW, Coughlin SR. Determinants of thrombin receptor cleavage. Receptor domains involved, specificity, and role of the P3 aspartate. J Biol Chem. 1995 Jul 7; 270(27):16435-40. PMID: 7608215
Prepared: November 29, 2018
28 of 42
39. Nanevicz T, Ishii M, Wang L, Chen M, Chen J, Turck CW, Cohen FE, Coughlin SR. Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J Biol Chem. 1995 Sep 15; 270(37):21619-25. PMID: 7665575
40. Chen J, Bernstein HS, Chen M, Wang L, Ishii M, Turck CW, Coughlin SR. Tethered ligand library for discovery of peptide agonists. J Biol Chem. 1995 Oct 6; 270(40):23398-401. PMID: 7559498
41. Isik FF, Coughlin SR, Nelken NA, Clowes AW, Gordon D. JE gene expression in an animal model of acute arterial graft rejection. J Surg Res. 1996 Jan; 60(1):224-31. PMID: 8592418
42. Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR. Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling. J Biol Chem. 1996 Jan 12; 271(2):702-6. PMID: 8557676
43. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, Kahn M, Nelken NA, Coughlin SR, Payan DG, Bunnett NW. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996 Mar 15; 314 ( Pt 3):1009-16. PMID: 8615752
44. Kahn M, Ishii K, Kuo WL, Piper M, Connolly A, Shi YP, Wu R, Lin CC, Coughlin SR. Conserved structure and adjacent location of the thrombin receptor and protease-activated receptor 2 genes define a protease-activated receptor gene cluster. Mol Med. 1996 May; 2(3):349-57. PMID: 8784787
45. Brown JL, Stowers L, Baer M, Trejo J, Coughlin S, Chant J. Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway. Curr Biol. 1996 May 1; 6(5):598-605. PMID: 8805275
46. Connolly AJ, Ishihara H, Kahn ML, Farese RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996 Jun 6; 381(6582):516-9. PMID: 8632823
47. Lerner DJ, Chen M, Tram T, Coughlin SR. Agonist recognition by proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function. J Biol Chem. 1996 Jun 14; 271(24):13943-7. PMID: 8662993
48. Kranzhöfer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW, Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res. 1996 Aug; 79(2):286-94. PMID: 8756006
49. Trejo J, Connolly AJ, Coughlin SR. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J Biol Chem. 1996 Aug 30; 271(35):21536-41. PMID: 8702939
50. Franci C, Gosling J, Tsou CL, Coughlin SR, Charo IF. Phosphorylation by a G protein-coupled kinase inhibits signaling and promotes internalization of the monocyte chemoattractant protein-1 receptor. Critical role of carboxyl-tail serines/threonines in receptor function. J Immunol. 1996 Dec 15; 157(12):5606-12. PMID: 8955213
51. Shapiro MJ, Trejo J, Zeng D, Coughlin SR. Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonist-triggered versus tonic internalization and intracellular localization. J Biol Chem. 1996 Dec 20; 271(51):32874-80. PMID: 8955127
Prepared: November 29, 2018
29 of 42
52. Bernstein HS, Coughlin SR. Pombe Cdc5-related protein. A putative human transcription factor implicated in mitogen-activated signaling. J Biol Chem. 1997 Feb 28; 272(9):5833-7. PMID: 9038199
53. Molino M, Bainton DF, Hoxie JA, Coughlin SR, Brass LF. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem. 1997 Feb 28; 272(9):6011-7. PMID: 9038223
54. Verrall S, Ishii M, Chen M, Wang L, Tram T, Coughlin SR. The thrombin receptor second cytoplasmic loop confers coupling to Gq-like G proteins in chimeric receptors. Additional evidence for a common transmembrane signaling and G protein coupling mechanism in G protein-coupled receptors. J Biol Chem. 1997 Mar 14; 272(11):6898-902. PMID: 9054376
55. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature. 1997 Apr 3; 386(6624):502-6. PMID: 9087410
56. Connolly AJ, Suh DY, Hunt TK, Coughlin SR. Mice lacking the thrombin receptor, PAR1, have normal skin wound healing. Am J Pathol. 1997 Nov; 151(5):1199-204. PMID: 9358744
57. An S, Bleu T, Huang W, Hallmark OG, Coughlin SR, Goetzl EJ. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett. 1997 Nov 17; 417(3):279-82. PMID: 9409733
58. Bernstein HS, Coughlin SR. A mammalian homolog of fission yeast Cdc5 regulates G2 progression and mitotic entry. J Biol Chem. 1998 Feb 20; 273(8):4666-71. PMID: 9468527
59. Ishihara H, Zeng D, Connolly AJ, Tam C, Coughlin SR. Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood. 1998 Jun 1; 91(11):4152-7. PMID: 9596661
60. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature. 1998 Aug 13; 394(6694):690-4. PMID: 9716134
61. Kahn ML, Hammes SR, Botka C, Coughlin SR. Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. J Biol Chem. 1998 Sep 4; 273(36):23290-6. PMID: 9722561
62. Shapiro MJ, Coughlin SR. Separate signals for agonist-independent and agonist-triggered trafficking of protease-activated receptor 1. J Biol Chem. 1998 Oct 30; 273(44):29009-14. PMID: 9786906
63. Trejo J, Hammes SR, Coughlin SR. Termination of signaling by protease-activated receptor-1 is linked to lysosomal sorting. Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13698-702. PMID: 9811863
64. Trejo J, Coughlin SR. The cytoplasmic tails of protease-activated receptor-1 and substance P receptor specify sorting to lysosomes versus recycling. J Biol Chem. 1999 Jan 22; 274(4):2216-24. PMID: 9890984
65. Hammes SR, Coughlin SR. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1's tethered ligand. Biochemistry. 1999 Feb 23; 38(8):2486-93. PMID: 10029543
Prepared: November 29, 2018
30 of 42
66. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999 Mar; 103(6):879-87. PMID: 10079109
67. Sambrano GR, Coughlin SR. The carboxyl tail of protease-activated receptor-1 is required for chemotaxis. Correlation of signal termination and directional migration. J Biol Chem. 1999 Jul 16; 274(29):20178-84. PMID: 10400633
68. Hammes SR, Shapiro MJ, Coughlin SR. Shutoff and agonist-triggered internalization of protease-activated receptor 1 can be separated by mutation of putative phosphorylation sites in the cytoplasmic tail. Biochemistry. 1999 Jul 20; 38(29):9308-16. PMID: 10413505
69. Kahn ML, Diacovo TG, Bainton DF, Lanza F, Trejo J, Coughlin SR. Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and Do not exhibit a Bernard-Soulier phenotype. Blood. 1999 Dec 15; 94(12):4112-21. PMID: 10590056
70. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med. 2000 Feb 7; 191(3):455-62. PMID: 10662791
71. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000 Mar 10; 275(10):6819-23. PMID: 10702240
72. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000 Apr 6; 404(6778):609-13. PMID: 10766244
73. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000 May 9; 97(10):5255-60. PMID: 10805786
74. Faruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem. 2000 Jun 30; 275(26):19728-34. PMID: 10779527
75. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem. 2000 Aug 18; 275(33):25216-21. PMID: 10837487
76. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem. 2000 Aug 25; 275(34):26333-42. PMID: 10831593
77. Trejo J, Altschuler Y, Fu HW, Mostov KE, Coughlin SR. Protease-activated receptor-1 down-regulation: a mutant HeLa cell line suggests novel requirements for PAR1 phosphorylation and recruitment to clathrin-coated pits. J Biol Chem. 2000 Oct 6; 275(40):31255-65. PMID: 10893235
78. Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, Foy D, Hafezi-Moghadam A, Ley K. Delayed onset of inflammation in protease-activated receptor-2-deficient mice. J Immunol. 2000 Dec 1; 165(11):6504-10. PMID: 11086091
Prepared: November 29, 2018
31 of 42
79. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001 Aug 31; 293(5535):1666-70. PMID: 11533492
80. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001 Sep 6; 413(6851):74-8. PMID: 11544528
81. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem. 2002 May 3; 277(18):16081-7. PMID: 11850418
82. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. Blood. 2002 Nov 1; 100(9):3240-4. PMID: 12384423
83. Eisenhaure TM, Francis SA, Willison LD, Coughlin SR, Lerner DJ. The Rho guanine nucleotide exchange factor Lsc homo-oligomerizes and is negatively regulated through domains in its carboxyl terminus that are absent in novel splenic isoforms. J Biol Chem. 2003 Aug 15; 278(33):30975-84. PMID: 12773540
84. Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng A, Griffin C, Coughlin SR. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood. 2003 Nov 1; 102(9):3224-31. PMID: 12869501
85. Camerer E, Duong DN, Hamilton JR, Coughlin SR. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood. 2004 Jan 1; 103(1):152-4. PMID: 14504091
86. Ludeman MJ, Zheng YW, Ishii K, Coughlin SR. Regulated shedding of PAR1 N-terminal exodomain from endothelial cells. J Biol Chem. 2004 Apr 30; 279(18):18592-9. PMID: 14982936
87. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004 Jul 15; 104(2):397-401. PMID: 15031212
88. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost. 2004 Aug; 2(8):1429-35. PMID: 15304051
89. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon NL, Esmon CT, Coughlin SR. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem. 2005 Apr 1; 280(13):13122-8. PMID: 15665002
90. Ruppel* KM, Willison* D, Kataoka H, Wang A, Zheng YW, Cornelissen I, Yin L, Xu SM, Coughlin SR. Essential role for Galpha13 in endothelial cells during embryonic development. Proc Natl Acad Sci U S A. 2005 Jun 7; 102(23):8281-6. PMID: 15919816 *co-first
91. Su X, Camerer E, Hamilton JR, Coughlin SR, Matthay MA. Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms. J Immunol. 2005 Aug 15; 175(4):2598-605. PMID: 16081834
Prepared: November 29, 2018
32 of 42
92. Camerer E, Cornelissen I, Kataoka H, Duong DN, Zheng YW, Coughlin SR. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood. 2006 May 15; 107(10):3912-21. PMID: 16434493
93. De Candia E, Pecci A, Ciabattoni G, De Cristofaro R, Rutella S, Yao-Wu Z, Lazzareschi I, Landolfi R, Coughlin S, Balduini CL. Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives. J Thromb Haemost. 2007 Mar; 5(3):551-9. PMID: 17137471
94. Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A. 2007 Jan 2; 104(1):288-92. PMID: 17190826
95. Pappu R*, Schwab SR*, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG**, Coughlin SR**. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007 Apr 13; 316(5822):295-8. PMID: 17363629 *co-first; **co-corresponding
96. Cottrell GS, Amadesi S, Pikios S, Camerer E, Willardsen JA, Murphy BR, Caughey GH, Wolters PJ, Coughlin SR, Peterson A, Knecht W, Pothoulakis C, Bunnett NW, Grady EF. Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology. 2007 Jun; 132(7):2422-37. PMID: 17570216
97. Sood R, Zogg M, Westrick RJ, Guo YH, Kerschen EJ, Girardi G, Salmon JE, Coughlin SR, Weiler H. Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med. 2007 May 14; 204(5):1049-56. PMID: 17438064
98. Regard JB, Kataoka H, Cano DA, Camerer E, Yin L, Zheng YW, Scanlan TS, Hebrok M, Coughlin SR. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. J Clin Invest. 2007 Dec; 117(12):4034-43. PMID: 17992256
99. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest. 2008 Mar; 118(3):1123-31. PMID: 18292814
100. Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H. Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. Blood. 2008 Aug 1; 112(3):585-91. PMID: 18490515
101. Watanabe N, Bodin L, Pandey M, Krause M, Coughlin S, Boussiotis VA, Ginsberg MH, Shattil SJ. Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin alphaIIbbeta3. J Cell Biol. 2008 Jun 30; 181(7):1211-22. PMID: 18573917
102. Regard JB, Sato IT, Coughlin SR. Anatomical profiling of G protein-coupled receptor expression. Cell. 2008 Oct 31; 135(3):561-71. PMID: 18984166
103. Li G, Kataoka H, Coughlin SR, Pleasure SJ. Identification of a transient subpial neurogenic zone in the developing dentate gyrus and its regulation by Cxcl12 and reelin signaling. Development. 2009 Jan; 136(2):327-35. PMID: 19103804
104. Hamilton JR, Cornelissen I, Mountford JK, Coughlin SR. Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice. Atherosclerosis. 2009 Aug; 205(2):427-32. PMID: 19217621
Prepared: November 29, 2018
33 of 42
105. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, Pham TH, Wong JS, Pappu R, Coughlin SR. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009 Jul; 119(7):1871-9. PMID: 19603543
106. Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, Coughlin SR, McDonald DM, Schwab SR, Cyster JG. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med. 2010 Jan 18; 207(1):17-27. PMID: 20026661
107. Camerer E, Barker A, Duong DN, Ganesan R, Kataoka H, Cornelissen I, Darragh MR, Hussain A, Zheng YW, Srinivasan Y, Brown C, Xu SM, Regard JB, Lin CY, Craik CS, Kirchhofer D, Coughlin SR. Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell. 2010 Jan 19; 18(1):25-38. PMID: 20152175
108. Cornelissen I, Palmer D, David T, Wilsbacher L, Concengco C, Conley P, Pandey A, Coughlin SR. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 2010 Oct 26; 107(43):18605-10. PMID: 20930120
109. Green JA, Suzuki K, Cho B, Willison LD, Palmer D, Allen CD, Schmidt TH, Xu Y, Proia RL, Coughlin SR, Cyster JG. The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol. 2011 Jul; 12(7):672-80. PMID: 21642988
110. Shao B, Wahrenbrock MG, Yao L, David T, Coughlin SR, Xia L, Varki A, McEver RP. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood. 2011 Oct 13; 118(15):4015-23. PMID: 21860019
111. Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, Dorn GW, Cyster JG. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science. 2011 Sep 30; 333(6051):1898-903. PMID: 21960637
112. Regard JB, Cherman N, Palmer D, Kuznetsov SA, Celi FS, Guettier JM, Chen M, Bhattacharyya N, Wess J, Coughlin SR, Weinstein LS, Collins MT, Robey PG, Yang Y. Wnt/ß-catenin signaling is differentially regulated by Ga proteins and contributes to fibrous dysplasia. Proc Natl Acad Sci U S A. 2011 Dec 13; 108(50):20101-6. PMID: 22106277
113. Yang H, Kim A, David T, Palmer D, Jin T, Tien J, Huang F, Cheng T, Coughlin SR, Jan YN, Jan LY. TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell. 2012 Sep 28; 151(1):111-22. PMID: 23021219
114. Khoufache K, Berri F, Nacken W, Vogel AB, Delenne M, Camerer E, Coughlin SR, Carmeliet P, Lina B, Rimmelzwaan GF, Planz O, Ludwig S, Riteau B. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan 2; 123(1):206-14. PMID: 23202729
115. Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, Green HF, Pandey A, Dror RO, Shaw DE, Weis WI, Coughlin SR*, Kobilka BK*. High-resolution crystal structure of human protease-activated receptor 1. Nature. 2012 Dec 20; 492(7429):387-92. PMID: 23222541 *co-corresponding
116. Miller CN, Hartigan-O'Connor DJ, Lee MS, Laidlaw G, Cornelissen IP, Matloubian M, Coughlin SR, McDonald DM, McCune JM. IL-7 production in murine lymphatic endothelial
Prepared: November 29, 2018
34 of 42
cells and induction in the setting of peripheral lymphopenia. Int Immunol. 2013 Aug; 25(8):471-83. PMID: 23657000
117. Herzog BH, Fu Jianxin, Wilson SJ, Hess PR, Sen A, McDaniel JM, Pan Y, Sheng M, Yago T, Silasi-Mansat R, McGee S, May F, Nieswandt B, Morris, AJ, Lupu F, Coughlin SR, McEver RP, Chen H, Kahn ML, Xia L. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature. 2013 Oct 3: 502(7469)105-9. PMID: 23995678
118. Bynagari-Settipalli YS, Cornelissen I, Palmer D, Duong D, Concengco C, Ware J, Coughlin SR. Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. Arterioscler Thromb Vasc Biol. 2014 Dec; 34(12):2563-9. PMID: 25278288.
119. Edelstein LC, Simon LM, Lindsay CR, Kong X, Teruel-Montoya R, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, Holinstat M, Shaw CA, Bray PF. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood. 2014 Nov 27; 124(23):3450-8. PMID: 25293779.
120. Clay H, Coughlin SR. Mechanical vessel injury in zebrafish embryos. J Vis Exp. 2015; (96). PMID: 25742284.
121. Alsteens D, Pfreundschuh M, Zhang C, Spoerri PM, Coughlin SR, Kobilka BK, Müller DJ. Imaging G protein-coupled receptors while quantifying their ligand-binding free-energy landscape. Nat Methods. 2015 Sep; 12(9):845-51. PMID: 26167642
122. Berger M, Scheel DW, Macias H, Miyatsuka T, Kim H, Hoang P, Ku GM, Honig G, Liou A, Tang Y, Regard JB, Sharifnia P, Yu L, Wang J, Coughlin SR, Conklin BR, Deneris ES, Tecott LH, German MS. Gai/o-coupled receptor signaling restricts pancreatic ß-cell expansion. Proc Natl Acad Sci U S A. 2015 Mar 3; 112(9):2888-93. PMID: 25695968.
123. Prasad JM, Gorkun OV, Raghu H, Thornton S, Mullins ES, Palumbo JS, Ko YP, Höök M, David T, Coughlin SR, Degen JL, Flick MJ. Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. Blood. 2015 Oct 22; 126(17):2047-58. PMID: 26228483.
124. Wilsbacher LD, Coughlin SR. Analysis of Cardiomyocyte Development using Immunofluorescence in Embryonic Mouse Heart. J Vis Exp. 2015; (97). PMID: 25866997.
125. Page MJ, Lourenço AL, David T, LeBeau AM, Cattaruzza F, Castro HC, VanBrocklin HF, Coughlin SR, Craik CS. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nat Commun. 2015; 6:8448. PMID: 26423607.
126. Zou J, Tran D, Baalbaki M, Tang LF, Poon A, Pelonero A, Titus EW, Yuan C, Shi C, Patchava S, Halper E, Garg J, Movsesyan I, Yin C, Wu R, Wilsbacher LD, Liu J, Hager RL, Coughlin SR, Jinek M, Pullinger CR, Kane JP, Hart DO, Kwok PY, Deo RC. An internal promoter underlies the difference in disease severity between N- and C-terminal truncation mutations of Titin in zebrafish. Elife. 2015; 4. PMID: 26473617
127. Pfreundschuh M, Alsteens D, Wieneke R, Zhang C, Coughlin SR, Tampé R, Kobilka BK, Müller DJ. Identifying and quantifying two ligand-binding sites while imaging native human membrane receptors by AFM. Nat Commun. 2015; 6:8857. PMID: 26561004.
128. Orr N, Arnaout R, Gula LJ, Spears DA, Leong-Sit P, Li Q, Tarhuni W, Reischauer S, Chauhan VS, Borkovich M, Uppal S, Adler A, Coughlin SR, Stainier DY, Gollob MH. A
Prepared: November 29, 2018
35 of 42
mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. Nat Commun. 2016; 7:11303. PMID: 27066836.
129. Clay H, Wilsbacher LD, Wilson SJ, Duong DN, McDonald M, Lam I, Park KE, Chun J, Coughlin SR. Sphingosine 1-phosphate receptor-1 in cardiomyocytes is required for normal cardiac development. Dev Biol. 2016 Jun 19. pii: S0012-1606(15)30086-5. doi: 10.1016/j.ydbio.2016.06.024. [Epub ahead of print] PMID: 27333774
130. To T-L, Schepis A, Ruiz-Gonzalez R, Zhang Q, Yu D, Dong Z, Coughlin SR, Xhu X. Rational design of a GFP-based fluorogenic caspase reporter for imaging apoptosis in vivo. Cell Chemical Biology 2016 23(7):875-82 PMID: 27447051
131. David T, Kim YC, Ely L, Rondon I, Gao H, O'Brien P, Bolt MW, Coyle AJ, Garcia JL, Flounders EA, Mikita T, and Coughlin SR. Factor XIa-specific IgG and a reversal agent to probe FXI function in thrombosis and hemostasis. Science Translational Medicine 2016; 8(252):353ra112 PMID 27559095.
132. Gazit SL, Mariko B, Thérond P, Decouture B, Xiong Y, Couty L, Bonnin P, Baudrie V, Le Gall SM, Dizier B, Zoghdani N, Ransinan J, Hamilton JR, Gaussem P, Tharaux PL, Chun J, Coughlin SR, Bachelot-Loza C, Hla T, Ho-Tin-Noe B, Camerer E. Platelet and Erythrocyte Sources of S1P Are Redundant for Vascular Development and Homeostasis, but both Rendered Essential After Plasma S1P Depletion in Anaphylactic Shock. Circ. Res. 2016; Aug 31 Epub ahead of print PMID: 27582371
133. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegué E, Looney MR. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017 Apr 6;544(7648):105-109. doi: 10.1038/nature21706. Epub 2017 Mar 22. PMID: 28329764
134. Ely LK, Lolicato M, David T, Lowe K, Kim YC, Samuel D, Bessette P, Garcia JL, Mikita T, Minor DL, Coughlin SR. Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent. Structure. 2018 Jan 02. PMID: 29336885. PMCID: PMC5803430
135. Zhang Q, Huang H, Zhang L, Wu R, Chung CI, Zhang SQ, Torra J, Schepis A, Coughlin SR, Kornberg TB, Shu X. Visualizing Dynamics of Cell Signaling InVivo with a Phase Separation-Based Kinase Reporter. Mol Cell. 2018 Jan 18; 69(2):334-346.e4. PMID: 29307513. PMCID: PMC5788022
136. Schepis A, Barker A, Srinivasan Y, Balouch E, Zheng Y, Lam I, Clay H, Hsiao CD, Coughlin SR. Protease signaling regulates apical cell extrusion, cell contacts, and proliferation in epithelia. J Cell Biol. 2018 Mar 05; 217(3):1097-1112. PMID: 29301867. PMCID: PMC5839797
137. Jiang X, Wooderchak-Donahue WL, McDonald J, Ghatpande P, Baalbaki M, Sandoval M, Hart D, Clay H, Coughlin S, Lagna G, Bayrak-Toydemir P, Hata A. Inactivating mutations in Drosha mediate vascular abnormalities similar to hereditary hemorrhagic telangiectasia. Sci Signal. 2018 Jan 16; 11(513). PMID: 29339534. PMCID: PMC5811261
138. Zhang Q, Huang H, Zhang L, Wu R, Chung CI, Zhang SQ, Torra J, Schepis A, Coughlin SR, Kornberg TB, Shu X. Visualizing Dynamics of Cell Signaling InVivo with a Phase Separation-Based Kinase Reporter. Mol Cell. 2018 Jan 18; 69(2):347. PMID: 29351851
Prepared: November 29, 2018
36 of 42
139. Zhang Q, Zheng YW, Coughlin SR, Shu X. A rapid fluorogenic GPCR-ß-arrestin interaction assay. Protein Sci. 2018 Apr; 27(4):874-879. PMID: 29411438. PMCID: PMC5866937
140. Wu RS, Lam II, Clay H, Duong DN, Deo RC, Coughlin SR. A Rapid Method for Directed Gene Knockout for Screening in G0 Zebrafish. Dev Cell. 2018 Jul 02; 46(1):112-125.e4. PMID: 29974860
141. Bokoch MP, Jo H, Valcourt JR, Srinivasan Y, Pan AC, Capponi S, Grabe M, Dror RO, Shaw DE, DeGrado WF, Coughlin SR. Entry from the lipid bilayer: a possible pathway for inhibition of a peptide G protein-coupled receptor by a lipophilic small molecule. Biochemistry. 2018 Aug 13. PMID: 30102523
NON-PEER REVIEWED PUBLICATIONS 1. Carethers JM, Coughlin S, Diamond B, Erzurum S, Fried LP, Jameson JL, Kaushansky K,
Klotman ME, Lemon S, Mitchell B, Rothman P, Sawyers C, Seidman C, Somlo S. J Clin. Invest. 2014; 124(9):3680-1. PMCID: PMC4151225
REVIEW ARTICLES 1. Moskowitz, M.A. and Coughlin, S.R. Basic properties of prostaglandins. Stroke 1981 l2:
696‑70l.
2. Moskowitz, M.A. and Coughlin, S.R. Clinical applications of prostaglandins and their inhibitors. Stroke 1981 l2: 882‑886.
3. Williams, L.T., Escobedo, J.A., Keating, M.T., and Coughlin, S.R. The stimulation of paracrine and autocrine mitogenic pathways by the platelet‑derived growth factor receptor. J. Cell Physiol. 1987 Suppl. 5:27‑30.
4. Coughlin SR, Escobedo JA, Williams LT. Molecular mechanisms of platelet-derived growth factor action. Prog Clin Biol Res. 1988. 266:39-45. PMID: 2837788
5. Williams, L.T., Escobedo, J.A., Keating, M.T. and Coughlin, S.R. Signal transduction by the platelet‑derived growth factor receptor. Cold Spring Harbor Symposium on Quantitative Biology 1988. 53: 455‑465.
6. Coughlin, S.R., Vu, T.-K.H., Hung, D.T., and Wheaton, V.I. Perspectives. Characterization of the cloned platelet thrombin receptor: issues and opportunities. J. Clin. Invest. 1992. 89:351-355.
7. Coughlin, S.R., Vu, T.-K.H., Hung, D.T., and Wheaton, V.I. Expression cloning and characterization of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Seminars in Thrombosis and Hemostasis 1992. 18(2):161-166.
8. Coughlin, S.R., Scarborough, R.M., Vu, T.-K.H., and Hung, D.T. Thrombin receptor structure and function. Cold Spring Harbor Symposium on Quantitative Biology. The Cell Surface. 1993. 57: 149-154.
9. Coughlin, S.R. Thrombin receptor structure and function. Thrombosis and Haemostasis. 1993. 70(1): 184-187.
10. Coughlin, S.R. Thrombin receptor and cardiovascular disease. Trends in Cardiovascular Medicine 1994. 4(2):77-83.
Prepared: November 29, 2018
37 of 42
11. Coughlin, S.R. Molecular mechanisms of thrombin signaling. Seminars in Hematology. 1994. 31(4) 270-277.
12. Coughlin, S.R. Expanding horizons for G protein-coupled receptors: diversity and disease. 1994. Current Opinions in Cell Biology. 6(2): 191-197.
13. Coughlin, S.R. Protease activated receptors start a family. Proc. Natl. Acad. Sci. USA 1994. 91: 9200-9202.
14. Wilcox, J.N., Nelken, N.A., Coughlin, S.R., and Schall, T.H. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Athero. and Thrombos. 1994. Vol 1 (Suppl. 1): S10-S13.
15. Coughlin, S.R. How proteases talk to cells---Thrombin receptor recognition and activation. Proc. Alfred Benzon Symposium. Royal Danish Academy of Sciences. 1995.
16. Coughlin, S.R. How thrombin talks to cells: molecular mechanisms and roles in vivo (1997 Sol Sherry Lecture) Arteriosclerosis, Thrombosis, and Vascular Biology 1998. 18(4):514-518.
17. Coughlin, S.R. Protease-activated receptors and platelet function. Thrombosis and Haemostasis 1999. 82:353-356.
18. Coughlin, S.R. How the protease thrombin talks to cells. Proc. Natl. Acad. Sci. USA 1999. 96(20):11023-27.
19. Coughlin, S.R. Thrombin signaling and protease-activated receptors. Nature 2000. 407:258-264.
20. Coughlin, S.R. Protease-activated receptors in vascular biology. Thrombosis and Haemostasis 2001. 86:298-307.
21. Gilman, A.G. et al. Overview of the Alliance for Cellular Signaling. Nature 420(6916):703-6.
22. Coughlin, S.R. Protease-activated receptors in the cardiovascular system. 67th Cold Spring Harbor Symposium on Quantitative Biology 2002. 67:197-208.
23. Coughlin, S.R. PARticipation in inflammation. J. Clin. Invest. 2003. 111:25-7
24. Camerer, E. and Coughlin, S.R. Tickling PAR1: A role in APC signaling and barrier protection? Blood 2005. 105(8): 3004-5.
25. Coughlin, S.R. Protease-activated receptors in hemostasis, thrombosis, and vascular biology. State of the Art Chapter. J. Thromb. Haemost. 2005. 3(8):1800-14.
26. Eagle KA, Ginsburg GS, Musunuru K, Aird WC, Balalban RS, Bennett SK, Blumenthal RS, Coughlin SR, Davidson KW, Frolich ED, Greenland P, Jarvik GP, Libby P, Pepine CJ, Ruskin JN, Stillman AE, Van Eyk JE, Tolunay HE, McDonald CL, Smith SC Jr. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: Report of NHLBI working group. Circulation 2010. 121(12): 1447-54.
27. Carethers JM, Coughlin S, Diamond B, Erzurum S, Fried LP, Jameson JL, Kaushansky K, Klotman ME, Lemon S, Mitchell B, Rothman P, Sawyers C, Seidman C, Somlo S. The imperative to invest in science has never been greater. J Clin Invest. 2014 Sep 2; 124(9):3680-1.
Prepared: November 29, 2018
38 of 42
BOOKS AND CHAPTERS
1. Coughlin, S. (1981) Regulation of Vascular Prostacyclin Synthesis, Ph.D. Thesis, Massachusetts Institute of Technology.
2. Coughlin, S. and Williams, L.T. (1984) Antithrombotic therapy and the acute ischemic syndromes. In Acute Coronary Care, (Califf, R. and Wagner, G., Eds.) Boston, Martinus Nijhoff Publishing, pp 135‑144.
3. Williams, L., Tremble, P., Daniel, T., Coughlin, S., Giels, G., and Wang, J. (1985) Platelet‑derived growth factor receptors in normal and transformed cells. In Cold Spring Harbor Symposium on Cancer Cells: Growth Factors and Transformation, (Feramisco, J., Ozanne, B. and Stiles, C., Eds.), New York: Cold Spring Harbor Press, pp 175‑182.
4. Kiwak, K.J., Coughlin, S.R., and Moskowitz, M.A. (1986) Arachidonic acid metabolism in brain blood vessels: implication for the pathogenesis and treatment of cerebrovascular diseases. In Stroke, Pathophysiology, Diagnosis, and Management (Barnett, H., Stein, B., Mohr, J., And Yatsu, F. Eds.) New York: Churchill‑Livingston, pp 141‑164.
5. Williams, L.T., Daniel, T.O., Escobedo, J.A., Fried, V.A., and Coughlin, S.R. (1986) PDGF Receptors: Structural and functional studies. In Advances in Gene Technology: Molecular Biology of the Endocrine System (Puett, D., Ahmad, F., Black, S., Lopez. D., Melner, M., Scott, W., And Whelan, W., Eds.) New York: Cambridge University Press, pp 168‑171.
6. Williams, L.T., and Coughlin, S.R. (1986) Cardiovascular growth factors. In Handbook of Experimental Cardiology (Fozzard, H.M., Haber, E., Jennings, R., Katz,
7. Williams, L.T., Escobedo, J.A., Coughlin, S.R., and Keating, M.T. Expression and function of the PDGF receptor in normal and transformed cells. In Growth Factors and Cancer (M.E. Lippman, editor), in press.
8. Williams, L.T., Coughlin, S.R., Escobedo, J.A., Starksen, N.F., and Keating, M.T., (1988) The expression of genes involved in the mitogenic response to platelet‑derived growth factor. In Mechanisms of Control of Gene Expression, (B. Cullen, L.T. Gage, M.A.Q. Siddiqui, A.M. Skalka, and H. Weissbach, editors), 67:351‑358.
9. Coughlin, S., Escobedo, J., and Williams, L.T. (1988) Molecular mechanisms of platelet‑derived growth factor action. In Second International Symposium on Tissue Repair (Barbul, A., Pines, E., Caldwell, M., and Hunt, T.K., Eds.) New York, Allan R. Liss, Inc. pp 39‑45.
10. Coughlin, S.R., and Keating, M.T. (1989) The platelet‑derived growth factor system. In Oncogenes (Benz, C. and Liu, E., Eds.) Kluwer Academic Publishers, Norwell, MA. pp 169-176.
Prepared: November 29, 2018
39 of 42
11. Coughlin, S.R., (1991) Thrombosis and vascular biology. In: Cardiology (Parmley, W. W. and Chatterjee, K., Eds.) J. B. Lippincott, NY; Vol. 1, Ch. 6. pp 1-10.
12. Coughlin, S.R. (1997) The platelet thrombin receptor. In: The Platelet (Lapetina, E.G., Ed.) JAI Press, Greenwich, CT pp129-143.
13. Coughlin, S.R. (1995) The platelet thrombin receptor. In: Molecular Biology of Thrombosis and Hemostasis. (Roberts, H.R., and High, K.A., Eds.) Marcel Dekker, Inc., NY. pp 639-649.
14. Cantley, L.C. and Coughlin, S.R., Editors (1997) Current Opinion in Cell Biology. Vol. 9, No. 2. Cell Regulation.
15. Coughlin, S.R. (2003) Protease-activated receptors. In: Handbook of Cell Signaling. Bradshaw R. and Dennis E., Editors. Elsevier.
16. Coughlin, S.R., Camerer, E., and Hamilton, J.R. (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Lippinncott. Eds. Colman R. et al.
SIGNIFICANT PUBLICATIONS 1. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin
receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991 Mar 22; 64(6):1057-68. PMID: 1672265
Identified the first protease-activated receptor, PAR1, and the molecular mechanism by which the protease thrombin activates platelets and other cells. Initiated the project, designed the experiments, did much of the laboratory work, interpreted the data, wrote the paper.
2. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991 Oct 17; 353(6345):674-7. PMID: 1717851
Confirmed the proteolytic activation mechanism put forward in #1. Initiated the project, designed the experiments, did much of the laboratory work, interpreted the data, wrote the paper.
3. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature. 1998 Aug 13; 394(6694):690-4. PMID: 9716134
Identified PAR3 and PAR4, the two remaining thrombin receptors in the mammalian genome. Initiated and guided project, designed experiments with Dr. Kahn, interpreted data, wrote paper.
4. Trejo J, Hammes SR, Coughlin SR. Termination of signaling by protease-activated receptor-1 is linked to lysosomal sorting. Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13698-702. PMID: 9811863
With other studies from the lab, this paper answered the question of how signaling by an irreversibly activated receptor is terminated. Initiated and guided project, designed experiments with Dr.Trejo, interpreted data, wrote paper.
Prepared: November 29, 2018
40 of 42
5. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999 Mar; 103(6):879-87. PMID: 10079109
This paper established that PAR1 and PAR4 together account for activation by thrombin and their relative roles. It was important for stimulating and sustaining interest in PAR1 as a possible target for antithrombotic therapy. Initiated and guided project, designed experiments with Dr. Kahn, interpreted data, wrote paper.
6. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001 Aug 31; 293(5535):1666-70. PMID: 11533492
Identified a role for thrombin signaling outside the context of response to injury. Specifically, PAR1 function in endothelial cells appears to be necessary for hemostasis and vascular integrity during embryonic development. Initiated and guided project, designed experiments with Ms. Griffin, interpreted data, wrote paper.
7. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001 Sep 6; 413(6851):74-8. PMID: 11544528
Established a necessary role for PARs in platelet activation by thrombin by use of knockout mice. Initiated and guided project, designed experiments with Dr.Sambrano, interpreted data, wrote paper.
8. Camerer E, Duong DN, Hamilton JR, Coughlin SR. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood. 2004 Jan 1; 103(1):152-4. PMID: 14504091
Revealed that, together, platelet activation via PARs and fibrin formation account for the importance of thrombin for hemostasis in vivo. Initiated and guided project, designed experiments with Dr. Camerer, interpreted data, wrote paper.
9. Pappu R*, Schwab SR*, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG**, Coughlin SR**. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007 Apr 13; 316(5822):295-8. PMID: 17363629 *co-first; **co-corresponding
This paper represented a new direction for the lab. Intrigued by the high levels of S1P1, the GPCR for sphingosine-1-phosphate (S1P), in endothelial cells and the high level of S1P in plasma, we set out to identify the sources and importance of plasma S1P. This paper reports that is supplied to plasma mainly by hematopoietic cells but is supplied to lymph by a different cell type (which we later found to be lymphatic endothelium). Other data confirmed that S1P is indeed very low in the interstitium and that this gradient permits S1P in lymph to function as an exit signal necessary for egress of lymphocytes from lymph nodes into lymph and lymphoid organs into blood. Initiated the project, and designed experiments, interpreted the data and wrote paper with Drs. Pappu, Schwab and Cyster.
Prepared: November 29, 2018
41 of 42
10. Regard JB, Sato IT, Coughlin SR. Anatomical profiling of G protein-coupled receptor expression. Cell. 2008 Oct 31; 135(3):561-71. PMID: 18984166
This paper provided a valuable resource for investigators seeking to use mouse models to probe GPCR function. Initiated and guided project, and designed experiments, interpreted data, wrote paper with Dr. Regard.
11. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, Pham TH, Wong JS, Pappu R, Coughlin SR. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009 Jul; 119(7):1871-9. PMID: 19603543
Demonstrated a critical role for plasma S1P in maintaining vascular integrity and regulating responses to leak inducing agents in the adult. Initiated and guided project, and designed experiments, interpreted data, wrote paper with Dr. Camerer.
12. Camerer E, Barker A, Duong DN, Ganesan R, Kataoka H, Cornelissen I, Darragh MR, Hussain A, Zheng YW, Srinivasan Y, Brown C, Xu SM, Regard JB, Lin CY, Craik CS, Kirchhofer D, Coughlin SR. Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell. 2010 Jan 19; 18(1):25-38. PMID: 20152175
This study revealed an unexpected role for PARs in neural tube closure in the mouse and, more broadly, an unexpected role in regulating epithelial behaviors. It also pointed to PAR2 as a possible physiological substrate for the membrane-tethered protease matriptase, suggesting a local protease-receptor network may regulate epithelial cell behavior. Initiated and guided project, and designed experiments, interpreted data, wrote paper with Dr.Camerer.
13. Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, Green HF, Pandey A, Dror RO, Shaw DE, Weis WI, Coughlin SR*, Kobilka BK*. High-resolution crystal structure of human protease-activated receptor 1. Nature. 2012 Dec 20; 492(7429):387-92. PMID: 23222541 *co-corresponding
The first PAR structure. This off state structure of PAR1 in complex with the drug vorapaxar explained how this drug functions as an irreversible PAR1 antagonist and suggested unusual mechanisms of drug entry and specificity. The structure also revealed substantial differences between PAR1 and previously crystallized GPCRs; these differences suggest that different classes of GPCRs may use different molecular mechanisms to stabilize their off state and to transmit conformational changes across the membrane. The structure also provided know-how that positions us to obtain an on-state structure to identify in detail how the PAR1 tethered ligand activates the receptor and how PAR1 can couple to G1, Gq and G12. This was a team effort between the Coughlin and Kobilka labs. I initiated the project and guided it together with Dr. Kobilka. We wrote the paper together.
PATENTS ISSUED OR PENDING 1. multiple patents issued to UC
OTHER CREATIVE ACTIVITIES
1. />
Prepared: November 29, 2018
42 of 42
ADDITIONAL RELEVANT INFORMATION Per Web of Knowledge, cited 25523 times, H-index 81.